Expression levels of TWIST1 are associated with the clinicopathological stage of B‑cell non‑Hodgkin lymphoma

Jia,Cundong; Liang,Liping; Yang,Lili; Zhao,Feng; Bai,Jingping

doi:10.3892/etm.2014.1962

November-2014 Volume 8 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November-2014 Volume 8 Issue 5

Full Size Image

Article

Expression levels of TWIST1 are associated with the clinicopathological stage of B‑cell non‑Hodgkin lymphoma

Authors:
- Cundong Jia
- Liping Liang
- Lili Yang
- Feng Zhao
- Jingping Bai
View Affiliations / Copyright

Affiliations: Department of Medical Oncology, The Affiliated Tumor Hospital of Xinjiang Medical University, Ürümqi, Xinjiang 830011, P.R. China, Department of Pathology, The Affiliated Tumor Hospital of Xinjiang Medical University, Ürümqi, Xinjiang 830011, P.R. China, Department of Bone Oncology, The Affiliated Tumor Hospital of Xinjiang Medical University, Ürümqi, Xinjiang 830011, P.R. China
Pages: 1489-1493
|
Published online on: September 15, 2014

https://doi.org/10.3892/etm.2014.1962
Expand metrics +

Abstract

The aim of the present study was to investigate the expression level of TWIST1 in B‑cell non‑Hodgkin lymphoma (BNHL) and its association with the clinicopathological characteristics of BNHL. Expression levels of TWIST1 were analyzed in patients with BNHL (n=45) and lymphadenosis (n=21) using immunohistochemical staining and western blot analysis. In addition, the mRNA expression levels of TWIST1 in the peripheral blood were detected by fluorescent quantitative polymerase chain reaction. The positive rate of TWIST1 expression in the BNHL tissue was 82.2%, which was significantly higher compared with the lymphadenosis tissue (5%; P<0.05). In addition, the protein expression level of TWIST1 in the BNHL tissue was higher compared with the lymphadenosis tissue. TWIST1 expression was also higher in stage III/IV BNHL tissues than in stage I/II tissues (P<0.05). The tissues were staged following the Ann Arbor system. Furthermore, the mRNA expression level of TWIST1 in the peripheral blood of the BNHL tissue (3.03±0.03) was higher compared with the lymphadenosis tissue, and the mRNA expression level of TWIST1 was higher in stage III/IV (4.41±0.12) tissues than in stage I/II BNHL (2.03±0.08) tissues. In conclusion, TWIST1 expression was higher in the tissue and peripheral blood of patients with BNHL when compared with those with lymphadenosis. Thus, TWIST1 expression was associated with the clinicopathological stage of BNHL.

View Figures

View References

1	Maxwell SA and Mousavi-Fard S: Non-Hodgkin’s B-cell lymphoma: advances in molecular strategies targeting drug resistance. Exp Biol Med (Maywood). 238:971–990. 2013.
2	Griffin MM and Morley N: Rituximab in the treatment of non-Hodgkin’s lymphoma - a critical evaluation of randomized controlled trials. Expert Opin Biol Ther. 13:803–811. 2013.
3	Goldman S, Smith L, Anderson JR, et al: Rituximab and FAB/LMB 96 chemotherapy in children with stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology Group report. Leukemia. 27:1174–1177. 2013.PubMed/NCBI
4	Hitz F, Fischer N, Pabst T, et al: Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial. Ann Hematol. 92:1033–1040. 2013. View Article : Google Scholar : PubMed/NCBI
5	Xu PP, Wang Y, Shen Y, et al: Prognostic factors of Chinese patients with T/NK-cell lymphoma: a single institution study of 170 patients. Med Oncol. 29:2176–2182. 2012. View Article : Google Scholar : PubMed/NCBI
6	Friedberg JW, Byrtek M, Link BK, et al: Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol. 30:3368–3375. 2012. View Article : Google Scholar : PubMed/NCBI
7	Morin RD and Gascoyne RD: Newly identified mechanisms in B-cell non-Hodgkin lymphomas uncovered by next-generation sequencing. Semin Hematol. 50:303–313. 2013. View Article : Google Scholar : PubMed/NCBI
8	Rehn S, Glimelius B, Strang P, et al: Prognostic significance of flow cytometry studies in B-cell non-Hodgkin lymphoma. Hematol Oncol. 8:1–12. 1990. View Article : Google Scholar : PubMed/NCBI
9	Xue G and Hemmings BA: Phosphorylation of basic helix-loop-helix transcription factor TWIST1 in development and disease. Biochem Soc Trans. 40:90–93. 2012. View Article : Google Scholar : PubMed/NCBI
10	Weiss MB, Abel EV, Mayberry MM, et al: TWIST11 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells. Cancer Res. 72:6382–6392. 2012. View Article : Google Scholar : PubMed/NCBI
11	Roschewski M, Staudt LM and Wilson WH: Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 11:12–23. 2014. View Article : Google Scholar : PubMed/NCBI
12	Cheng GZ, Chan J, Wang Q, et al: TWIST1 transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res. 67:1979–1987. 2007. View Article : Google Scholar : PubMed/NCBI
13	Ogura M, Hatake K, Ando K, et al: Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Sci. 103:933–938. 2012. View Article : Google Scholar : PubMed/NCBI
14	Qin Q, Xu Y, He T, et al: Normal and disease-related biological functions of TWIST11 and underlying molecular mechanisms. Cell Res. 22:90–106. 2012. View Article : Google Scholar : PubMed/NCBI
15	Takeuchi M, Sato Y and Yoshino T: The frequency of malignant lymphoma subtypes based on World Health Organization (WHO) classification. Nihon Rinsho. 72:436–440. 2014.PubMed/NCBI
16	Ciobanu A, Stanca O, Triantafyllidis I, et al: Indolent lymphoma: diagnosis and prognosis in medical practice. Maedica (Buchar). 8:338–342. 2013.PubMed/NCBI
17	Lange J and Burkhardt B: Treatment of adolescents with aggressive B-cell malignancies: the pediatric experience. Curr Hematol Malig Rep. 8:226–235. 2013. View Article : Google Scholar : PubMed/NCBI
18	Na YR, Lee JS, Lee SJ and Seok SH: Interleukin-6-induced TWIST1 and N-cadherin enhance melanoma cell metastasis. Melanoma Res. 23:434–443. 2013. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Expression levels of TWIST1 are associated with the clinicopathological stage of B‑cell non‑Hodgkin lymphoma

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles